Bial reports positive results from Phase III studies of seizure drug
In addition, treatment with Zebinix also significantly improved patient quality of life, reduced depressive symptoms and demonstrated sustained reduction in partial seizure frequency during a one-year open label
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.